-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pfizer Inc. has announced a deal with Gilead Sciences to produce the antiviral drug reedsivir developed by Gilead to help fight the COVID-19 pandemic.
under the agreement, Pfizer will provide contract manufacturing services at its McPherson, Kansas, plant to produce and supply Redcywe, Gilead. "From the beginning, it was clear that no company could end the COVID-19 crisis," said Albert Bourla, chief executive of Pfizer,
.
this requires this pharmaceutical industry system to work together to provide solutions."
it is unclear whether Pfizer is only available to the U.S. market.
meanwhile, Gilead aims to produce a sufficient number of Redsevetoby by the end of this year to treat more than 2 million PATIENTs with COVID-19, and the U.S. recently purchased almost all antiviral drugs as of September.
Gilead says the drug's production network has grown to more than 40 companies in North America, Europe and Asia to increase production capacity.
May, Gilead entered into a licensing agreement with five generic drug makers to produce Redseveinin in 127 countries, excluding the United States.
since then, the agreement has been extended to nine drugmakers, including Hikma Pharmaceuticals, which says it has started production of Redseve at its Portuguese plant.
said in June that in the U.S. and other developed countries, Redcywe was priced at $390 per bottle and a five-day course of six bottles at a cost of $2,340 per patient.
.
